Founded in 1995, the AIDS Vaccine Advocacy Coalition (AVAC) is a non-profit, community- and consumer-based organization that uses public education, policy analysis, advocacy and community mobilization to accelerate the ethical development and global delivery of AIDS vaccines and other HIV prevention options.
Making sense of the PAVE 100 debate: New tools for HIV prevention advocates
Click here for updates on PAVE 100 and to download new documents designed to help advocates, community groups and other stakeholders understand some of the key questions that have been raised in discussions about PAVE 100.
--------------------------------------------------------------------------------------------------------------------------
AVAC Report 2008
(click to enlarge)
-------------------------------------------------------------------------------------------------------------------------
A call for accuracy, a call for respect
AVAC comments following the NIH Summit on HIV Vaccine Research and Development
(March 26, 2008)
-------------------------------------------------------------------------------------------------------------------------
Px Wire
AVAC announces the launch of its new quarterly update, Px Wire
**Visit www.pxwire.org for details--click here to download the current issue**
-------------------------------------------------------------------------------------------------------------------------
Updated information on MRK-Ad5 vaccine trials, the AIDS Vaccine Summit and AVAC's perspective
- AVAC's response to Washington Post article, March 21, 2008
- Click here to read the February 27th Advocates' Network update
- Download AVAC's report on the December 12, 2007 meeting of the AIDS Vaccine Research Subcommittee (AVRS) of the NIH AIDS Research Advisory Committee
PDF - HTML
Click here for additional coverage of the Merck vaccine trials
-------------------------------------------------------------------------------------------------------------------------
The announcement of the failure of the leading AIDS vaccine candidate developed by Merck & Co. is another in a series of disappointing setbacks in HIV prevention. How we as a global community choose to respond to this news, however, is the real test. More...
Op-ed by Glenda Gray, co-director of the Perinatal HIV Research Unit in South Africa and AVAC Executive Director Mitchell Warren, published in the Seattle Post-Intelligencer
-------------------------------------------------------------------------------------------------------------------------
AVAC's publications and continuous policy, advocacy, education and outreach work is made possible by the dedicated labor of AVAC advocates and support from Broadway Cares/Equity Fights AIDS, the Ford Foundation, the Bill &
Melinda Gates Foundation, the Global HIV Vaccine Enterprise, the International AIDS Vaccine Initiative, the International Partnership for Microbicides, Until There's a Cure Foundation®, the WHO-UNAIDS HIV Vaccine Initiative, UNAIDS, and many generous individuals who have become AVAC Members.
